18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma

Journal of Nuclear Medicine

Volumn 43, Issue 1, 2002, Pages 66-71

  Szakáll Jr , Szabolcs ^a   Ésik, Olga ^a   Bajzik, Gábor ^a   Repa, Imre ^a   Dabasi, Gabriella ^a   Sinkovics, István ^a   Ágoston, Péter ^a   Trón, Lajos ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

18F FDG; Lymph node metastasis; Medullary thyroid cancer; PET

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CALCITONIN; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID MEDULLARY CARCINOMA; TUMOR LOCALIZATION; WHOLE BODY SCINTISCANNING; BLOOD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LYMPH NODE; MEDULLARY CARCINOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; THYROID TUMOR;

CALCITONIN; CARCINOMA, MEDULLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 0036007410     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Medullary thyroid carcinoma: Recent advances and management update
2. Frequency and significance of cervicomediastinal lymph node metastases in medullary thyroid carcinoma: Results of a compartment-oriented microdissection method
3. Prognostic factors in medullary thyroid carcinomas: Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content
4. Management of medullary carcinoma of the thyroid
5. Clinical characteristics in sporadic and familial medullary thyroid carcinoma: A nationwide study of 249 patients in Sweden from 1959 through 1981
6. Calcitonin and carcinoembryonic antigen as tumour markers in medullary thyroid carcinoma
7. Localization and resection of clinically inapparent medullary carcinoma of the thyroid
8. Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma
9. Ultrasound diagnosis of C-cell carcinoma of the thyroid
10. Recurrent occult thyroid carcinoma detected by MR imaging
11. Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: High sensitivity of selective venous catheterization
12. Diagnostic procedure before reoperation in patients with medullary thyroid carcinoma
13. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: A comparative study
14. Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging
15. New radionuclide tracers for the diagnosis and therapy of the medullary thyroid carcinoma
16. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma
17. Technetium-99-sestamibi scanning in recurrent medullary thyroid carcinoma
18. Positive anticalcitonin immunoscintigraphy in patients with medullary thyroid carcinoma
19. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer
20. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG): 5 Years of experience
21. 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid
22. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma
23. The application of PET in clinical oncology
24. Imaging of metastases of thyroid carcinoma with fluorine-18-fluorodeoxyglucose
25. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicenter study
26. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: Implications for diagnosis and therapy
27. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer
28. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer
29. Fluorine-18 fluoro-deoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer
30. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide
31. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography
32. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine turnouts
33. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: A clinical and molecular study
34. Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma
35. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer
36. Reoperation in metastasizing medullary thyroid carcinoma: Is a tumour stage-oriented approach justified?
37. Angiography effectively supports the diagnosis of hepatic metastases in medullary thyroid carcinoma
38. Current approaches and perspectives in the therapy of medullary thyroid carcinoma
39. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection
40. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis